Your session is about to expire
← Back to Search
Anifrolumab for Lupus
Study Summary
This trial will test whether the drug anifrolumab improves blood vessel function and reduces blood vessel inflammation in people with SLE.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am between 18 and 80 years old.I am generally healthy or have been diagnosed with lupus according to specific criteria.I am vaccinated against COVID-19 and Varicella Zoster or have antibodies.I haven't had major surgery in the last 8 weeks and don't plan any during the study.My lupus treatment has been stable for at least 4 weeks.My medications for diabetes, high blood pressure, or cholesterol have been stable for the last 3 months.I have been taking 10 mg or less of Prednisone daily for at least 2 weeks.
- Group 1: Patient placebo
- Group 2: Patient
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there an opportunity for individuals to join this research endeavor?
"The details on clinicaltrials.gov show that this medical trial has ceased patient recruitment, with the last revision being made on November 30th 2022. However, 637 alternative trials are currently seeking participants."
Is it possible for me to partake in this experiment?
"For this research, applicants must possess systemic lupus erythematosus and be between 18 to 80 years of age. 45 individuals will take part in the trial."
Does this research encompass participants who are octogenarian and older?
"This clinical trial only allows adults aged 18 to 80 years old. The research team has identified 47 trials intended for minors, and 566 studies open to the elderly population."
Has Patient obtained its final FDA authorization?
"As this is a Phase 1 trial, the safety of Patient has been estimated to be relatively low with a score of 1. This means there is limited data regarding its efficacy and potential side effects."
Share this study with friends
Copy Link
Messenger